NRG-GY032
Phase II
OPEN TO ACCRUAL
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)
NRG-GY035
Phase III
OPEN TO ACCRUAL
A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer